AI speeds adapting to post-COVID ‘new normal’: WhizAI
Outsourcing Pharma
NOVEMBER 12, 2020
A leader from the AI technology firm discusses how life-sciences pros are harnessing AI to help continue their work in the face of the pandemic.
Outsourcing Pharma
NOVEMBER 12, 2020
A leader from the AI technology firm discusses how life-sciences pros are harnessing AI to help continue their work in the face of the pandemic.
pharmaphorum
NOVEMBER 11, 2020
Abid Rahman from Intouch Group tells pharmaphorum how AI-based technology is solving challenges across healthcare systems, pharmaceutical companies, and patient treatment. With AI already the key engine for a growing list of consumer devices, the trend has created exciting opportunities for pharma and healthcare. “We have now entered a new phase of AI implementation where AI-based technology is expected to be foundational and not just a novel technology,” Abid Rahman, vice president, innovation,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Druggist
NOVEMBER 13, 2020
Ibuprofen is a common medication used in the management of pain, fever, and to reduce inflammation. Alongside paracetamol (Calpol) it is one of the first medicines considered by parents when a child is ill. However, ibuprofen may not be recommended as the drug of choice in a particular group of children or to treat specific conditions. Today I answer the question: Can you use ibuprofen for chickenpox?
Pharma Marketing Network
NOVEMBER 13, 2020
On November 12, 2020, The Pharma CX Tech Summit held their third annual conference. The topics focused on the emerging technologies that pharma is implementing to enhance customer experiences for patients, payers, and HCPs. These technologies include AI/ML, voice & chat, connected devices, AR/VR, automation, personalization, and telehealth. . During the summit, speakers shared their thoughts and opinions on new technologies, how to prioritize customer experiences during COVID-19, and their
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Outsourcing Pharma
NOVEMBER 12, 2020
The two companies plan to work together on the creation a drug-development technology tool that helps in safety margin risk assessment prediction.
pharmaphorum
NOVEMBER 11, 2020
In the second positive piece of COVID-19 vaccine news in a week, Russia’s Sputnik V candidate has been shown to be 92% effective at the interim point of a 40,000-patient study. The preliminary assessment is based on 20 coronavirus cases split between the vaccinated and placebo arms of the study at 21 days, according to a press statement issued this morning by the Gamaleya Institute which developed the shot and the Russian Direct Investment Fund (RDIF).
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharma Marketing Network
NOVEMBER 12, 2020
Healthcare Internet Conference ( HCIC) | November 16-19, 2020 | VIRTUAL. Greystone.Net’s annual Healthcare Internet Conference (HCIC) is the premier conference for healthcare marketing, IT, web, data analytics, business development, public relations and communication leaders who are responsible for their organization’s public-facing websites, intranets, portals, social channels, mobile strategy and CRM strategies.
Outsourcing Pharma
NOVEMBER 10, 2020
The two companies have joined forces to collaborate on the commercial launch of Gimoti, a nasal spray for patients suffering from diabetic gastroparesis.
pharmaphorum
NOVEMBER 11, 2020
In the first episode of our Health Innovators series, Paul Tunnah speaks to David Van Sickle, CEO of Propeller Health about how digital technologies are revolutionising the field of respiratory medicine. The post Health Innovators: David Van Sickle on digital innovation in respiratory medicine appeared first on.
Med Ed 101
NOVEMBER 11, 2020
Irritable bowel syndrome can be very difficult to manage in some patients and once controlled, you can imagine that the patient wants nothing more than to keep their symptoms at bay. I’ve seen medications that exacerbate IBS-diarrhea used in clinical practice and really upset the balance of control. Here are a few of the more […]. The post Medications That Exacerbate IBS-Diarrhea appeared first on Med Ed 101.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Marketing Network
NOVEMBER 11, 2020
Re:Imagine Pharma Marketing: How Pharma Marketing is Evolving in 2020. On November 9-11, 2020, Imagine Pharma Marketing held a virtual conference that discussed the roadmap for embedding long term commercial evolution in marketing. This event focused on the many different changes that are happening in pharma marketing due to COVID and what the industry’s future may look like.
Outsourcing Pharma
NOVEMBER 10, 2020
Preliminary results from a recent clinical trial indicate the drug touted by US leaders as a possible treatment offers no significant benefit to patients.
pharmaphorum
NOVEMBER 12, 2020
CatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy targeting Growth Differentiation Factor 15 (GDF-15). The round was led by Vesalius Biocapital III, with participation from Novartis Venture Fund (NVF), Wachstumsfonds Bayern, coparion and founding investors Forbion and BioGeneration Ventures.
Pharma Times
NOVEMBER 12, 2020
Interim data analysis comes from phase III clinical trials in the Russian Federation
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Druggist
NOVEMBER 10, 2020
Calpol is probably the most well-known brand of paracetamol in liquid form for infants, toddlers and children. Calpol range of paracetamol liquid includes Calpol Infant and Calpol 6+. Today I will list Calpol alternative products, including other brands and forms of liquid paracetamol and alternative drugs. Although the intention is to find Calpol alternative products for toddlers and children, I included a few products, which have a minimum age restriction of 12 years and above.
Outsourcing Pharma
NOVEMBER 9, 2020
President-elect Joe Biden has launched a Transition COVID-19 Advisory Board to support the USâ COVID-19 response.
pharmaphorum
NOVEMBER 12, 2020
The European Union has ordered 300 million doses of BioNTech/Pfizer’s COVID-19 vaccine following this week’s landmark announcement that it was effective in more than 90% of patients. The companies said deliveries of an initial order of 200 million vaccines will be subject to approval by European regulators and are expected to start by the end of this year.
Pharma Times
NOVEMBER 9, 2020
Phase III study of vaccine candidate involved 43,538 participants
pharmaphorum
NOVEMBER 13, 2020
Since Covid-19 hit, many industries have shifted a heavier weighting of their business into the online world, relying on e-commerce and digital engagement to counterbalance the reduced ability for physical interactions. The pharma world is no exception, and this year both small and large players have made the transition – partly out of necessity – from a world that relied predominantly on the face-to-face side of doing business, into a new digital world.
pharmaphorum
NOVEMBER 9, 2020
The FDA may have been minded to approve Biogen and Eisai’s Alzheimer’s candidate aducanumab, but its clinical advisors have little doubt that the evidence for the drug is lacking. The much-anticipated advisory committee meeting held on Friday to discuss the marketing application for aducanumab proved to be a fractious affair, with both the companies’ data – and some of the FDA’s interpretation of it – under fire by panellists.
pharmaphorum
NOVEMBER 13, 2020
US data analysis company Palantir Technologies could be drafted in to manage the UK government’s troubled COVID-19 Test and Trace programme, according to press reports. Palantir has been linked with the project for several weeks and the Financial Times is the latest to suggest that the company could get involved with the troubled project. Palantir was founded in 2003 by a team including paypal co-founder Peter Thiel and the company’s billionaire CEO Alex Karp.
pharmaphorum
NOVEMBER 9, 2020
As the death toll from COVID19 inexorably mounts, Pfizer and BioNTech have announced that their COVID-19 vaccine candidate is more than 90% effective at countering the disease in an interim analysis. The companies said they will be ready to file the vaccine with the FDA in the third week of November once they have enough safety data to meet the regulator’s requirements.
pharmaphorum
NOVEMBER 9, 2020
There isn’t enough evidence to suggest that digital therapies for people with opioid use disorder (OUD) can improve on standard interventions, according to the Institute for Clinical and Economic Review. The US cost-effectiveness watchdog has concluded in an evidence report that none of three digital therapies under scrutiny – apps from Pear Therapeutics, Chess Health and DynamiCare Health – have data from a randomised clinical trial showing they can enhance long-term abstinence or retention rat
pharmaphorum
NOVEMBER 10, 2020
DigitalHealth.London has announced the latest 20 small and medium sized businesses selected for its digital accelerator programme. The programme selects digital solutions or services with the highest potential to meet the city’s health and social care challenges. This the fifth year the event has been running and the NHS delivered programme will see funding matched by the European Regional Development Fund.
pharmaphorum
NOVEMBER 12, 2020
Swiss startup Synendos Therapeutics has raised CHF 20 million (almost $22 million) in first-round financing that will be used to develop its endocannabinoid drugs for central nervous system disorders. The Basel-based biotech – which was incubated in Switzerland’s BaseLaunch accelerator – is concentrating on developing a new class of small-molecule drugs for anxiety, mood and stress-related disorders.
pharmaphorum
NOVEMBER 9, 2020
COVID-19 has sparked a flurry of research and discoveries are being made at an unprecedented rate – but patient participation cannot and should not be left behind in the rush, say leading voices. SARS-CoV-2 has demonstrated both the strengths and the weaknesses of the life sciences ecosystem, and it is now up to the sector to learn and to lead. While trials of COVID-19 vaccines and treatments have accelerated at a hitherto unimaginable rate, work in other conditions has been halted and paused, b
pharmaphorum
NOVEMBER 12, 2020
Finnish startup Popit has joined with Spain’s Almirall to produce an app that tracks whether patients have taken their psoriasis medicine and sends them a reminder if they miss a dose. Popit’s technology, which is available in the Netherlands, is clinically validated to reduce the number of missed doses and has been already used by several pharma companies.
pharmaphorum
NOVEMBER 10, 2020
Digital therapeutics are gaining momentum worldwide and offer developers, including pharma, both a huge opportunity and a stimulating market access challenge, say Olaf Schoeman and Emanuele Arcà. The last 12 months have shone a spotlight on digital transformation in Europe’s healthcare systems, with all the signs pointing to digital therapeutics (DTx) moving ever more into the healthcare mainstream.
pharmaphorum
NOVEMBER 12, 2020
In the hours after Pfizer’s momentous vaccine news emerged on Monday #pfizerproud popped up on my social media feeds again and again from the firm’s employees, both past and present. I’ve been an avid observer of pharma social media for some time and this is somewhat unusual. Not for the pharma employees to be proud of the work they do, but such a spontaneous and widespread demonstration of pride in our industry is not normally seen, though it is thoroughly deserved here.
pharmaphorum
NOVEMBER 13, 2020
It’s day two of digital health innovation conference Frontiers Health, which will be mainly held online because of the COVID-19 pandemic. This year Frontiers will be a global Hybrid conference. In line with the “new normal” situation, the format of the 2020 edition will be hybrid combining online global streaming together with offline events and activities held at hubs in multiple locations such as Italy, Germany, Finland, Spain, the USA and more.
pharmaphorum
NOVEMBER 11, 2020
Digital health innovation conference Frontiers Health kicks off its 2020 edition this week, although the majority of the conference will be held online because of the COVID-19 pandemic. This year, Frontiers will be a global Hybrid conference. In line with the “new normal” situation, the format of the 2020 edition will be hybrid, combining online global streaming together with offline events and activities held at hubs in multiple locations such as Italy, Germany, Finland, Spain, the USA and m
pharmaphorum
NOVEMBER 10, 2020
As part of our series looking at how pharma companies have adapted to the pandemic, Shannon Rush, leader of Eli Lilly & Co’s diabetes business unit in Northern Europe, tells pharmaphorum how the company is working to support diabetes care in the UK amid the pandemic. As COVID-19 turned the world on its head, healthcare services for people living with long-term conditions like diabetes, came under a huge strain.
pharmaphorum
NOVEMBER 13, 2020
Janssen has submitted a new combination regimen for its blockbuster multiple myeloma drug Darzalex for approval with the FDA and EMA, hoping to give the treatment another edge over emerging competitors. Specifically, the combination utilises the subcutaneous formulation of the drug, Darzalex Faspro (daratumumab/hyaluronidase) with Celgene’s multiple myeloma drug Imnovid (pomalidomide) and dexamethasone – which has gained new fame this year as one of the few treatments available for COVID-19.
pharmaphorum
NOVEMBER 13, 2020
Janette Curlis is a Multiple Sclerosis Nurse Advisor (MSNA) at Biogen, helping to support the company’s Multiple Sclerosis (MS) field teams and developing patient and Healthcare Professional (HCP) materials. We spoke to her about being a bridge between pharma and the NHS and the challenges that are facing Multiple Sclerosis Nurses (MSNs) and patients today.
Let's personalize your content